Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
From www.bloodjournal.org by guest on June 14, 2017. For personal use only. Human T-cell Leukemia Virus Type I t a x h e x DNA and RNA in Cutaneous T-cell Lymphoma By Subrata K. Ghosh, J. Todd Abrams, Hiroshi Terunuma, Eric C. Vonderheid, and Elaine DeFreitas Peripheral blood mononuclear cells (PBMCs) and T-cell lines from patients with Sezary syndrome (SS) and skin lesions from patients with mycosis fungoides(MF) were examined by polymerase chain reaction (PCR) for DNA sequences homologousto thehuman retroviruses human T-lymphotropic virus (HTLV)-I and -11. Results obtained using primers and probes from the taxhex region of HTLV-I indicatethat 72% (18/25) of SS patients PBMCs, 8OYo (20/25) of T-celllines established from SS-PBMC, and 30% (3/10) of skin lesions from MF patients were positive for HTLV-I taxhex region DNA. Sequence analysis of the 127-bp fragment amplified by the tax/rexprimers from 4 of these individualswas found to be identical to that in prototypic HTLV-I. Negative results were obtained using primers and probes from the HTLV-I gag region and the HTLV-II gag and tax regions. No PCR products were obtained using all primers and probes using DNA from 9 healthy blood donors and 10 cord bloods. Expression of HTLV-I tax/rex mRNA was found in 4 of 8 Sezary patients, as determined by RNA-PCR, indicating that this viral regionis being transcribedin vivo. Exposureto Tax/Rex protein in SS-patients is supported by the fact that serum antibodies against p27"" and p40"" was observed in 43% and 29% of these SS patients, respectively. Although the causal relationship between the HTLV-I taxhex region and cutaneous T-cell lymphoma (CTCL) remains unclear, these findings support the presence of atruncated HTLV-I retrovirus in CTCL patients. 0 1994 by The American Society of Hematology. C for the expression of t d r e x mRNA inthe PBMCs of several SS patients. UTANEOUS T-CELL lymphoma (CTCL) is a lowgrade malignancy thought tobegin in the skin and then to be involved in the lymphoid tissue, peripheral blood, and visceral organs.'.' CTCL includes mycosis fungoides (MF) and the leukemic variant called Sezary syndrome (SS). SS is characterized by circulating clonal neoplastic T cells with cerebriform nuclei and a surface phenotype that is typically CD3+, CD4' and CD45 R o + . ~ The etiology of CTCL remains unknown. Because CTCL has clinical, pathologic, and immunogic similarities with human T-lymphotropic virus-I (HTLV-I)-associated adult Tcell leukemia (ATL), weand other investigators have attempted to determine whether a retroviral agent is involved with its pathogenesis. In 1987, Manzari et a14 observed budding retroviral-like particles from CTCL cells and designated them HTLV-V. This virus has not yet beenmolecularly characterized. In 1991, Hall et a 'lsuggested that a partially deleted HTLV-I provirus is associated with MF in non-HTLVI endemic areas. In the same year, Zucker-Franklin et a16.' reported HTLV-I-like particles in cultured lymphocytes of 18 of 20 consecutive MF patients. Recently, reports from these investigators indicate the presence of tax gene specific for both HTLV-I and HTLV-I1in peripheral blood mononuclear cells (PBMCs) from a patient with MF.' A small percentage of patients with classical MF have serum antibodies directed against HTLV-L9 Serologic studies by enzymelinked immunosorbent assay (ELISA) on more than 200 American patients with CTCL showed that less than 1% were HTLV seropositive. Subsequently, it was also shown that 11% of CTCL patients in Europe had low titers of antibody against HTLV-I antigen." To establish an in vitro model for CTCL, our laboratory successfully established interleukin-2 (IL-2)-responsive Tcell lines from blood of 25 American patients with SS3 who were HTLV-I seronegative by ELISA." To detect the presence of HTLV-I provirus present in these cell lines, we used semiquantitative polymerase chain reaction (PCR)." We report here the preferential retention of the HTLV-I tax/rex region but not the gag region in studies with 25 SS patients, using PBMCs, T-cell lines established from SS PBMCs, and skin biopsy specimens from 10 HTLV-I-seronegative MF patients. In addition, we provide evidence for the first report Blood, Vol 84, No 8 (October 15). 1994: pp 2663-2671 MATERIALS AND METHODS Cell isolation and culture. Peripheral blood obtained from several patients with SS was fractionated by Ficoll-Hypaque density centrifugation to recover PBMCs and to establish cell lines as described by Abrams et al." Oligonucleotide preparationand location of primers and probes. All the oligonucleotides were synthesized on automated DNA synthesizer (Model 380; Applied Biosystems, Foster City, CA) and were purified by high performance liquid chromatography for use as probe; 50 to 100 pmol of an oligonucleotide was end-labeled by T4 polynucleotide kinase (GIBCO, Grand Island, NY) withhigh specific activity y (3zP)dATP (NEN, Boston, MA) and separated on a Sephadex G-50 (Pharmacia, Piscataway, NJ). The amplification primers were (1) G-1-1 (+) (863-886), (3-1-2 (-) (1353-1379), and G-1-3 (probe) (1080-1101) corresponding to HTLV-I gag genome (product size, 535 bp); (2) G-2-2 (+) (813-838). G-2-1 (-) (11871214), and G-2-3 (probe) (1080-1105) corresponding toHTLV-I1 gag genome (product size, 409 bp); (3) T-1-1 (+) (7598-7619). T1-2 (-) (7703-7724), and T-1-3 (probe) (7675-7700) corresponding toHTLV-I radrex genome (product size, 127 bp); (4) T-2-1 (+) (7602-7620), T-2-2 (-) (7900-7920), and T-2-3 (probe) (7819-7846) corresponding to HTLV-I1 tax genome (product size, 319 bp); (5) T-1,2-1 (+) (7248-7267), T-1,2-2 (-) (7386-7406), andT-1.2-3 (probe) (7337-7376) corresponding to bases of HTLV-I1 tax genome From the Department of Medicine, University of Miami, School of Medicine, and Miami Veterans Administration Medical Center, Miami, FL; and the Department of Medicine, Divisionof Dermatology, Hahnemann University, Philadelphia, PA. Submitted December 10, 1993; accepted June 8,1994. Supported by National Institutes of Health Grant No. CA-48484 (E.D.), the American CancerSociety (E.D.), the Eleanor Naylor Dana Foundation (E.D.),and the Concern Foundation (J.T.A). Address reprint request to Subrata K . Ghosh, PhD, University of Miami, School of Medicine,Department of Medicine,PO Box 016960 (M818), Miami, FL 33101. The publication costsof this article were defrayedin part by page chargepayment. This article must therefore behereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. 0 1994 by The American Society of Hematology. 0006-4971/94/8408-0026$3.00/0 2663 From www.bloodjournal.org by guest on June 14, 2017. For personal use only. 2664 (product size, 159 bp), this region is also common to HTLV-I and -11 tar HTLV-Iand -11 areGenbankaccessionnos. J02029 and K02532, respectively. Isolation of DNA. DNA was extracted from the patient's freshly isolated PBMCs as well as from cultured T cellsby sodium dodecyl sulfate (SDS)/proteinaseK digestion followed by phenol-chloroform extraction using a nucleic acid extractor (Applied Biosystems). Control DNA was prepared from PBMCs obtained from cord bloods as well as healthyindividuals,MT-2(HTLV-Iinfected),andMOT (HTLV-I1 infected) cell lines. The DNA was removed from the filter ( 5 U precipitettecartridge;AppliedBiosystems)bydissolving in double distilled water. DNA concentration were estimated by mea260/280. DNA extraction was performed suring optical density at with freshly made reagents and equipment that is physically separated from pre- and post-PCR reagents and equipment. Amplijcation and analysis of amplijed DNA. PCRwasconductedafter initial optimizationofMgz+concentration of each primer set (datanot shown). Two micrograms of DNA was amplified through 30 repetitive three-step cycles of PCR with incubations for 1 minuteeachat 95°C and 55°C andfor 2 minutesatthe 72°C extension temperature. All amplifications were performed in a Perkin-Elmer Cetus Thermal Cycler (Perkin-Elmer Cetus, Norwalk, CT) in wells tested for uniform PCR product generation. The 100 pL of PCR reaction mixture contained 2 pg of sample DNA; 278 pmol/L each of dATP, dCTP, dGTP, and TTP; 0.8 pmol/L of each primer: 10 mmol/L Tris/HCI (pH 8.3); 50 mmol/L KCI; 1.5 of mmol/L MgClz (except for PCR of HTLV-I ?&rex region, in which optimum MgClzconcentrationis0.75 mmoUL); 0.01% (wt/vol)gelatin (Sigma, St Louis, MO); and2.5 U of Thermus aquaticus polymerase (Taq) enzyme" (Perkin-Elmer Cetus). We performed DNA extraction and PCR in separate areas using positive displacement pipettor toavoidcontamination.AfterPCR, 25 p L of the final amplified reaction product was analyzed by electrophoresis on 1.2% agarose gel ( 1 50 V for 2 to 3 hours). The gel was denatured and neutralized andtheDNAweretransferredtoNytrannylonmembrane (S&S Nytran) by blotting. Thefilter was soaked with2X SSC for5 minutes at room temperature and baked at 80°C for 2 hours under vacuum. The prehybridization buffer consists of 6X SSC, 0.5% SDS, 50% formamide, 5 X Denhardt's solution, and 150 pg/mL herring sperm DNA. The filter was prehybridized overnight at 37°C and then hybridized overnight with 5' end-labeled (12 X IOh cpm) probe (specific for the appropriate region) in prehybridization buffer. Filters were then washed with (I)2 X SSC/O.I% SDS (two times for 20 minutes at room temperature),(2) 0.2X SSC/O.I% SDS for 20 minutes at room temperature, (3) 0.1 x SSC/O.I% SDS (30 minutes at 37°C and l hour at 45°C). Autoradiography was performed with two intensifying screens (Cronex Hi Plans; Dupont, Wilmington, DE) at -70°C with Kodak X-AR-5 film (Eastman Kodak, Rochester, NY). The sensitivity of PCR results was determined by extracting DNA from HTLV-I (13-4) or HTLV-I1 (MO-T) producer serially diluted (20 ng, 2 ng, 200 pg, and 20 pg) with 2 pg HTLV-I, I1 negative U937 cellular DNA, and then subjected to PCR analysis. RNA isolation. Total RNA was isolated from either SS-PBMC or MT-2 cell line by a modification of the guanidinium isothiocyanate method of Chomczynski et al.'4 Reversetranscription and PCR(RNA-PCR). RNA-PCRwas performedas d e ~ c r i b e d 'with ~ minormodification. Briefly, total RNAs (2 pg) from SS PBMCs was treated with IO U of DNase I (RNase free; Boehringer Mannheim, Indianapolis, IN)30for minutes at 25"C, followed by 5 minutes at 100°C. This treated RNA then annealed with 2.5 pmol/L of a random hexamer primer and was reverse transcribed into cDNA in reaction mixture 20 pL (5 mmol/ L MgCI2, 1 mmol/L each of dATP, TTP, dGTP, dCTP, 1 U RNase inhibitor,2 pL 10 X reactionbuffer) by adding 2.5 U Moloney murine leukemia virus reverse transcriptase (Perkin-Elmer Cetus) at GHOSH ET AL 42°C for 45 minutes followed by a denaturation of enzyme at 99°C for 5 minutes. The resulting cDNA (20 pL) were added to X 0 pL of PCR cocktail (PCR buffer 11 without MgCI?), S0 pmol of each 5' (T-1-1) and 3' (T-1-2) primer (from tudr(>x region of HTLV-I genome), and 2.5 U of taq polymerase (Perkin-Elmer Cetus). PCR was performed in DNA Thermal Cycler (Perkin-Elmer Cetus) for of 40 cycles as described before. Because optimum concentration MgCI2 in PCR usingaboveprimer is 0.75mmol/Lnoadditional MgCI, is required for PCR step. Analysis of RT-PCR product in gel was performed exactly as described above for regular PCR. Cloning and sequencing ofthe umplified fragment. After amplification, the PCR-generated product was directly cloned into PCR IIvector (supplied with PCR I1 cloning kit; Invitrogen. San Diego. CA) transformed into Escherichia coli and, after plating. incubated overnight at 37°C. The resulting colonies were screened by a "P end-labeled oligonucleotide probe (T- 1-3). The cloned DNA were purified from E coli and sequenced by the dideoxy chain termination method of Sanger et all" with T7 DNA polymerase (Sequenase; US Biochemical Corp, Cleveland, OH) and a-(''S)-dATP. Reversetrunscriptnse L I S S U ~ . To detect potential virus,culture fluid washarvestedfromthreecycles of freezing at -80°C and subsequent thawing and was then centrifuged in a Sorval RC-SB at 2,000 rpm for IO minutes at 4°C to remove intact cells. The supernatant fluid was then recentrifuged at 10.000 rpm for l5 minutesto sediment cellular debris. Finally, potential viral particles were pelleted at 25,000 rpm for 90 minutes in an SW 28 rotor in a Beckman ultracentrifuge. The pellet was suspended in 500 p L ( l00X concentration)TNEbuffer (10 mmol/LTris/HCI, pH 8.0, 100 mmol/L NaCI, I mmol/L EDTA) and tested immediately. The reverse transcriptase activity was determined i n a reaction mixture of 1 0 0 pL containing S0 mmol/L Tris/HCI, pH 8.0,40 mmol/L KCI. 30 mmol/ L MgCI,, 5 mmol/L dithiothreitol (DTT), 0.05% TritonX-100, 0.2% Nonidet P-40 (NP-40), 100 pg/mL bovine serum albumin, 40 pg/mL template-primer complex poly (I€) oligo (dG) (Pharmacia). After S minutes on ice, 6.6 pmol/L ('H) dGTP (I1 Ci/mmol); Amersham, Arlington Heights, IL) was added to the mixture and incubated at 37°C for 60 minutes with repeated shaking. Thereaction was stopped by the addition of ice-cold 10 mmol/L sodium pyrophosphate and l S % trichloracetic acid (TCA). After 15 minutes at 0°C. the TCA precipitable ('H) poly G synthesized in this reaction was collected on glass microfibre filters (Whatman GF/C; 2.4 cm) presoaked in 5% TCA. Thefilters washed 10 times with ice-cold 5% TCA, dried. placed in scintillation cocktail, and counted." Wesrrrn blot analysis. The procedure for Western blot analysis of retroviral protein has been described by severallaboratories.Ix Proteins of HTLV-I from MT-2lysates were separated by SDSpolyacrylamide gel electrophoresis andthen transferred to nitrocellulose paper in a transblot electrophoresis cell (BioRad Laboratories, Richmond, CA) at 250 mA for 4 hours following the manufacturer's instructions. The nitrocellulose sheets were cut i n strips. To detect the binding of patient sera to reactive proteins. we used the ProtoBlot I1 AP system with stabilized substrate for human primary antibodies (Promega, Madison, WI) following the manufacturer's instructions for standard protocol. which can detect as little as S O pg protein. RESULTS Enzymatic gene amplification with HTLV-I t a d r e x primer on fresh PBMCs and T cells of SS patients. For the detection of HTLV-I tudrex sequence, DNA was prepared from fresh PBMCs and cultured T cells and tested for proviral DNA b y PCR. Amplification was performed using HTLV-I tudrex specific primer pairs (see Materialsand Methods) and analyzed by hybridization with a "P-labeled tudrex region oligonucleotide probe (T- 1-3). In titration experiments with From www.bloodjournal.org by guest on June 14, 2017. For personal use only. HTLV-I TAX/R€X 127 - IN CTCL 2665 I Fig 1. Analysis of PCR-amplified DNA extracted from SS PBMCs. The primers used were specific for HTLV-I tax/rex gene. The HTLV-I tax/ rex-specific oligonucleotide probe used for hybridization was T-1-3 with several concentrations of 13-4 cell line DNA known to be infected with HTLV-I that served as a positive control. DNA from U937 cell line and MOT cell line (HTLV-II positive) was the negative control. The line is the location of the expected 127-bp PCR product using these primers. positive control DNA, we found that the limit of detection lies between 20 and 200 pg DNA with this primer pair. The PCR results illustrated in Figs 1 and 2 indicate that I8 (72%) S S patients' PBMCs of 25 tested were positive for HTLVI radrex DNA, whereas 20 (80%) of 25 T-cell lines from S S patients were positive for this same region. Only 1 S S patient's PBMCs (SZ-32) were foundtobe negative for HTLV-I radrex gene sequence, whereas the derived T-cell line was positive. Negative results were obtained with DNA from the blood of healthy donors (9 PBMCs and I O cord bloods), confirming the specificity of the amplification (Fig 3). Enzymatic gene ampl$cation of HTLV-I gag on DNA from PBMCs and T-cell lines of SSpatienfs. After initial examination with HTLV-I radrex primers, DNA samples derived frombothPBMCsand cell lines with S S were amplified with synthetic oligonucleotides belonging to three different regions of HTLV-I and HTLV-I1 viral genomes (see Materials and Methods). The primer pairs ((3-1-1 and G-1-2) specific for HTLV-I gag (see Materials and Methods) region (representing a 535-bp nucleotide base sequence) were used to amplify DNA from PBMCs and T-cell lines. We could not detect any significant 535-bp gag product by hybridization with a gag-specific (G-1-3) oligonucleotide probe. However, we can detect between 20 and 200 pg when positive control DNA was subjected to PCR using these primers. The primer pairs T- 1,2-1 and T- 1,2-2, which amplify a conserved region of tax common to both HTLV-I and -11, were used to amplify 159 bp. The results were confirmed by repeated analysis and are summarized in Table I for PBMCs and in Table 2 for T-cell lines. We found 57% of S S PBMCs (12/ 2 1) and 54% of T-cell lines ( 1 3/24) to be positive.In titration experiments with positive control DNA, we found that the limit of detection lies between 200 pg and 2 ng. Negative results obtained using gag and f a x regions of HTLV-I1representing 409- and 3 19-bp nucleotide base sequences, respectively, were screened using specific primer pairs on these samples. Negative results indicate the absence of HTLV-I1 gag and tar genes. Healthy donors (9 PBMCs and 10 cord bloods) also tested negatively for HTLV-I rax/rex (observed Fig 2. Analysis of PCR-amplified DNA extracted from T-cell lines derived from SS PBMCs. The procedures were the same as for Fig 1. N-l, N-2, and N-4 represent negative controls (DNA from healthy individuals). From www.bloodjournal.org by guest on June 14, 2017. For personal use only. 2666 GHOSH ET AL -127 Fig 3. Analysis of PCR-amplifiedDNA extracted from control subjects. The primers and probe used were the same as for Fig 1. DNA from PBMCs of 9 healthy donors (Ph) and l0 cord blood (CB) served ascontrol subject. Different concentrations of DNA from 13-4cell line and MT2 (HTLV-I positive) were used as positive control and MOT (HTLV-II positive) was used as negative control. in S S patients and lines) as well as for gag I and I1 and tax I1 (data not shown). Nucleotide sequence analysis of PCR-amplijied products. To compare the sequence of tadrex PCR product (DNA from S S patients' blood andcell lines) with HTLV-Igenome, we cloned the 127-bp radrex PCR fragment into a plasmid vector (supplied with the kit, PCR I1 cloning kit; Invitrogen). EcoRI-digested plasmid was sequenced by dideoxy chain termination methodsI6 to characterize precisely the type of retrovirus by nucleotide comparison to the sequences of the HTLV-I genome. The comparative analysis of the sequence of tadrex from 4 S S patients (SZ-29 PBMC, SZ-4 cell line, SZ-28 cell line, and SZ-5 lymph node) to that of prototypic HTLV-I sequence indicates that the amplified product from S S patient DNA was identical to the prototype sequence of HTLV-I (7598 CAA TCA CTC ATA CAA CCC CCA ACA TTC CAC CCT CCT TCC TCC AGGCCA TGC GCA AATACTCCC CCTTCC GAA ATG GATACA TGG AAC CCA CCC TTG GGC AGC ACC TCC CAA CCC TGT CTT TTC CAG A 7724). Detection of HTLV-I tadrex mRNA in fresh PBMCs of SS patients. RNA-PCR was used to examine the expression of radrex mRNA in fresh PBMCs of S S patients. Total RNA was extracted from PBMCs and treated with DNase to eliminate potential DNA contamination. Then RNA (2 pg) was reverse transcribed to cDNA, followed by 40 cycles of PCR amplification using the HTLV-I radrex-specific primer pair. To determine the sensitivity of RNA-PCR, RNA from MT-2 cells were serially diluted (1: IO) and mixed with carrier totalRNA (2 pg) from normal PBMCs (HTLV-Inegative). A positive signal was detected when as little as 0.2 pg MT-2 mRNA was subjected to PCR, a IO' dilution. We have detected HTLV-I tadrex RNA in PBMC in 4 of 8 S S patients (Fig 4). PCR was performed without an RT step using DNase-treated RNA and produced no tadrex-specific products, confirming that DNA was not contaminating the RNA preparation (data not shown). RNA-dependent reverse transcriptase activiv. To detect retroviral RT activity, we measured the incorporation of ('H) GTP using synthetic homopolymer templates (Poly IC)and short oligodeoxy nucleotide primer (oligo dG). T-cellculture supernatants from 4 S S patients were concentrated by ultracentrifugation and tested for RT activity in presence of Mg2+ along with MT-2 (HTLV-I-positive) culture supernatant as a positive control. The data presented in Table 3 show that none of the cultured supernatants has any detectable Mg*+dependent activity, whereas MT-2 supernatants showed a typical poly IC oligo dG-dependent RT activity of HTLVI. Western blot analysis of patient serum against HTLVI antigen. Western blotting was performed to determine whether antibodies reactive with tax (p40)or rex (p27) proteins could be detected in S S serum. UsingMT-2 lysate proteins separated by SDS-PAGE and transferred to nitrocellulose as described in Materials and Methods, wetested serum or plasma from the individuals shown in Fig 5 . Sera from a patient with HAM (13-4) and an HTLV-I ELISApositive patient with cutaneous lymphoma (SZ-37) contained antibodies reactive with both gag and envproteins of HTLVI as well as with p27"" and p40'". Serum from a healthy donor served as a negative control (Ph-9). We found that 9 of 21 (43%) and 6 of 21 (29%) of S S patients contained antibodies reactive withp27"" and p4OIax, respectively, but not reactive with gag or env proteins. In total, 57% of these individuals contained antibodies reactive with either of these proteins. Detection of taxlrex gene in punch skin biopsies from patients with MF. To determine whether these observations could be extended to MF patients, we tested for the HTLVI tadrex gene in DNA extracted directly from skin punch From www.bloodjournal.org by guest on June 14, 2017. For personal use only. HTLV-I T A X ~ R E XIN 2667 CTCL Table 1. Enzymatic Gene Amplification of HTLV-I and -11 DNA Sequences in PBMCs From SS Patients gag I Patients sz-l sz-3 sz-5 s z - l0 sz-l2 sz-19 sz-20 sz-22 SZ-23 SZ-24 SZ-25 52-27 SZ-28 SZ-29 SZ-30 SZ-32 sz-33 sz-35 sz-37 SZ-38 sz-39 SZ-40 SZ-41 SZ-42 sz-45 Controls U937 13-4t (2 pg) 13-4 (20ng) 13-4 (2 ng) 13-4 (200 pg) 13-4 (20 pg) MOTS 12 pg) MOT (20ng) MOT (2 ng) MOT (200 pg) gag II taxl, II* taxVrexl + + + + + + + ND ND + - - + + - - ND ND + + + + + + + + + + + - - + + + + + - - - + - + - + + - - - - ND + + + + + - - - ND + ~~ ND ND ND ND ND ND ~~ taxll ~ Abbreviation: ND, not done. * Region amplified is conserved between HTLV-I and 4. t HTLV-l-positive cell line. HTLV-ll-positive cell line. * biopsy specimens from patients with MF. The high molecular weight (genomic) DNA (2 pg) obtained from skin lesion of 10 MF patients were subjected to PCR amplification with synthetic oligonucleotide primers specifically chosen to amplify 127-bp HTLV-I t d r e x and 535-bp gag (Materials and Methods) gene sequences, as described. Positive results were observed in 3 patients (30%) only when the tdrex-specific primer pair was used (Fig 6), whereas no 535-bp gag product was detected (data not shown). DISCUSSION We have detected the presence of the HTLV-I t d r e x gene (but not the gag gene) in DNA from PBMCs and Tcell line(s) from S S patients as well as in skin lesions from MF patients. The region detected by gene amplification was found to be identical by double stranded DNA sequencing to that of prototypic HTLV-I. No evidence of reverse transcriptase activity was found in supernatants from cell lines. Analysis of serum antibodies to HTLV-I by Western blot was negative for viral structural proteins, but a proportion of patients showed reactivity to p27*” and p40’”. We observed that the t d r e x gene is actively being transcribed by certain S S PBMCs as determined by RNA-PCR. These data indicate that these genes are being expressed in vivo, strengthening the possibility that t d r e x expression plays a role in the etiology of CTCL. However, the level of expression is less than that necessary for detection by Northem blot analysis. This observation is not surprising because similar results have been observed inPBMCs of patients with HTLV-I ATL, showing positive results with RNAPCRI9 without detection by Northern blot.” Table 2. Enzymatic Gene Amplification of HTLV-I and -11 DNA Seauences in T-cell Lines Derived From SS PBMCs Patients sz-l sz-2 sz-3 52-4 sz-5 SZ-6 sz-7 SZ-8 sz-10 SZ- 13 sz-20 sz-22 52-23 SZ-24 SZ-25 SZ-26 SZ-27 SZ-28 SZ-29 SZ-30 SZ-31 SZ-32 sz-33 sz-34 sz-35 Controls Normal 1 Normal 2 Normal 3 Normal 4 Normal 5 U937 13-4t (200 ng) 13-4 (20ng) 13-4 (2 ng) MOTS (200 ng) MOT (20 ng) MOT (2 na) - + + + + + + + + + - + + - + + + + + + + + + - ND ND - + + + ND - Abbreviation: ND, not done. * Region amplified is conserved between HTLV-I and -11. t HTLV-l-positive cell line. S HTLV-ll-positive cell line. From www.bloodjournal.org by guest on June 14, 2017. For personal use only. GHOSHETAL 2668 1 2 3 4 5 6 7 8 9 10 11 127- Fig 4. Detection of HTLV-I taxhex mRNA (DNase treated) in PBMCs of SS patients by RNAPCR. The primers and probe used were the same as for Fig 1. Lanes 1 through 8, total RNA extracted from SS patients SZ-3, SZ-20. SZ-21, SZ-23, SZ-27. SZ28. SZ-29, SZ-30. respectively; lanes 9 through 11, MT-2 cell RNA serially diluted with 2 p g RNAfrom normal PBMCs (HTLVI negative) and the amount of MT-2 RNA usedwas 20 pg, 2 pg, and 0.2 pg, respectively. -- HTLV-I, the first exogenous human retrovirus,2' was originally isolated from a patient considered to have S S and is now recognized as the etiological agent of ATL.2'*22The relationship between CTCL (MF and S S ) and ATL has not yet been clearly defined, but they share several features, ie, clonal T-cell transformation, skin involvement, and clinical similarity of end-stage disease. In contrast, ATL is an aggressive disorder, with rapid progression to death, whereas CTCL is more indolent. In ATL, HTLV-I provirus is integrated randomly into the abnormal T-cell population and the vast majority of the patients are seropositive for the structural proteins of HTLV-L2' In most ATL patients, serologic reactivity with HTLV-I tax protein has also been reported." The role of HTLV-I in the initiation and clonal expansion of CTCL is unknown. Manzari et a14 reported the detection of a new retrovirus, HTLV-V,in Italian MF patients and Hall et al' found a defective form of HTLV-I proviral DNA in MF patients. However, at least two reports were unable Table 3. RNA-Dependent Reverse Transcriptase Activity Sample sz-3 sz-3 sz-4 sz-4 SZ-28 SZ-28 sz-35 52-35 MT-2 MT-2 Templateffrimer (poly rC oligo dG1 + - + - + - + + TCA Precipitable 'H-dGTP (cpm) 2,005 1,534 775 624 1,389 1,463 1,045 875 993 11,193 Culture supernatants from SS cell line were concentrated 50x by ultracentrifugation (25,000 rpm in BeckmanSW28 rotorfor 90 minutes at 4°C). Reverse transcriptase activity was quantitated by the incorporation of 13HI-dGTP(specificactivity, 11 Cilmmol;ICNBiomedical) using a poly(rC)oligo(dG)12-18 (40 pg/mL) template-primer kit (Pharmacia). The reaction mixture contained 45 pmol/L labeled-dGTP as well as TrisRlCl(50 mmol/L) pH 8.0, MgCll (30 mmol/L), KC1 (40 mmoll L), Triton x - l 0 0 (0.05%).and dithiothreitol(5 pmol/L). Enzyme activity Materials and was assayedat 37°C. during 60 minutes as described in Methods. to confirm these observations using DNA from PBMCs and skin biopsies from patients with CTCL.24.2sNone of these studies reported testing of T-cell lines established from CTCL for detection of HTLV-I regions thatcanbeused to expand the potentially infected malignant cell. We have observed a stronger PCR signal in certain T-cell lines as compared with the PBMCs of that patient, suggesting potential expansion of the affected cell. The proviral genome of HTLV-I contains, in addition to the structural gene, a unique extra sequence, pX, located between the env gene and the 3' long terminal repeat (LTR)?' The pX regionis expressed as doubly spliced mRNA with tax (p40)and rex (p27) using two overlapping open reading frames2' thatregulate the replication of HTLVI at the transcriptional and posttranscriptional level, respect i ~ e l y . ~ "Recently, '~ Pancake and Zucker-Franklin' reported the presence of r u x gene common to HTLV-I and I1 in DNA from PBMCs of 6 MF patients, but it was not determined whether the agent detected was HTLV-I or -11. We have characterized the tadrex-amplified products by nucleotide sequence analysis. Results clearly demonstrate 100% homology with prototypic HTLV-Iin at least 4 patients (SZ-29 PBMC, SZ-4 cell line, SZ-28 cell line, and SZ-5 lymph node). The work presented here demonstrating the association ofa portion of the HTLV-I genome in certain S S patients blood issimilar to that of Hall et al' and Pancake and ZuckerFranklin' with respect to radrex DNA in CTCL. However, because of the absence of RT in our experiments, our data are more consistent the observations of Hall et al? Furthermore, we sent several S S PBMCs DNA samples to an independent laboratory, who confirmed our results (data not shown). The fact that the observations made here have not been found universally by all investigators who have performed similar experiments may relate to two important observations. First, titration of the Mgz+is critical for all primer pairs. In our hands, positive PCR products were best produced with the radrex-specific primers using 0.75 mmol/L Mgz+. Second, a nonintegrated form of tadrex gene has been found in the "Hido supernatants" from PBMCs and cell lines tested here (Ghosh et al, submitted for publication). The nonintegrated form of radrex gene may represent a significant portion of the DNA amplified in these individuals. From www.bloodjournal.org by guest on June 14, 2017. For personal use only. HTLV-I TMlREX IN CTCL 2669 30, p27 -b 21.5 1 2 7 36 5 4 8 9 10 15 14 13 12 11 1624 23 22 21 20 19 18 17 Fig 5. Antibodies to HTLV-I antigen detected in sera from patients with SS by Western blotting. Numbers at left indicate 40- and 27-kD proteins. Lane1, sera from a patient with TSP (13-4); lane 2, sera from an HTLV-l-positive SS patient (SZ-37); lane 3, sera from healthy donor (Ph-9); lanes4 through 24, sera from Sezary patients SZ-l, SZ-2, SZ-3. SZ-4. SZ-5. SZ-6, S Z - l . SZ-8, SZ-10. SZ-13, SZ-20. SZ-22, SZ-23, SZ-24, SZ-25, 52-26. SZ-27. SZ-28, SZ-29, 52-30. SZ-32, and SZ-35, respectively. Thus, extraction of only high molecular weight DNA rather than total DNA may reduce of a considerable portion of the signal we have observed. We believe that these methodologic points are the key to our consistent results. We suggest that such episomal radrex DNA are likely to be associated with a high molecular weight complex such as a retrotransposon." Why certain patients were found negative for radrex is unclear. However, the number of atypical cells does not appear to be the determining factor. For example, patients SZ-5 and SZ-27 were found to be PCR-positive, but contained less then 30% atypical cells, whereas patient SZ-32 was found to be negative, but contained 70% atypical cells. Conflicting data between PCR performed with the HTLV-I, I1 tax, and HTLV-I radrex primers is most likely due to the fact that we are able to detect lower amounts of viral DNA with the HTLV-I-specific primers (Table I). Positive results with SZ-41 PBMCs (Table 1) and SZ-l cell line (Table 2) for HTLV-I, I1 tax DNA, although negative for HTLV-I t a d rex DNA, is in contrast to the sensitivity for these primers. One possibility is that these cells retained the common tax DNA region while deleting the HTLV-I tadrex-specific region. Positive results for HTLV-I t d r e x andHTLV-I, I1 tax DNA in SZ-32 cell line may be due to expansion of taxcontaining cells from the blood. However, we do not know why SZ-32 PBMCs were found to be tadrex-negative when the number of atypical cells should have been sufficient to provide positive results. Although Zucker-Franklin et al' observed budding viral particles in short-term cultures of PBMCs from MF patients, no RT activity was demonstrated. To our knowledge, the only example of positive RT activity in CTCL was reported by Manzari et a1: in which activity was measured by using poly rA oligo dT and Mg2+and not with poly IC, oligo dG as template-primer. Because poly rA oligo dT can be used efficiently by cellular DNA polymerase, whereas poly rC oligo dG template is used poorly if at all by this enzyme,"2 positive RT results may be due to cellular DNA polymerase contamination. We are unable to demonstrate the presence of HTLV-I-specific RT activity (using poly rC oligo dG as template/primer and Mg2+ as divalent cation) in culture supernatant of S S cell line, which indicates either absence of HTLV-I whole virus or a virus with unknown template specificity or level of enzyme less than the detection limit. We could not identify any CTCL patient as being HTLVI seropositive by criteria established by the US Department of Health andHuman Services. However, 57% of CTCL patients tested were seropositive for the tax or rex regulatory proteins of HTLV-I. The percentage of antibody-positive individuals is less than the percentage of tadrex DNA-posi- control. but who contained antibodies reactive with the t d r e x gene From www.bloodjournal.org by guest on June 14, 2017. For personal use only. 2670 GHOSH ET A L Table 4. Summary of PCR and Antibodv Pattern for HTLV-I ~~ taxllrexl ______ Western Blot Lane Sample PBMCs T-cell Line P27 rex P40 tax 1 2 3 4 5 6 7 13-4 sz-37 Ph-9 + + + + + + + sz-l + sz-2 sz-3 sz-4 sz-5 SZ-6 sz-7 SZ-8 sz-l0 SZ-13 sz-20 sz-22 SZ-23 SZ-24 SZ-25 SZ-26 SZ-27 SZ-29 SZ-30 SZ-32 sz-35 NA a 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 - + NA + NA NA - MF patients, while not observing gag. Alternatively, these sequences could be associated with an exogenous retrovirus different from HTLV-I in the gag region; however. such a virus should have reverse transcriptase activity. Whether tux/ rex is associated with endogenous or exogenous sequences, we postulate that the expression of t d r e x maintains the malignant phenotype in CTCL. ACKNOWLEDGMENT + + We thank Joyce Stohler and Ryan Vestal for excellent technical assistance. NA NA NA + t + NA + + + NA + + + - + + +/- Abbreviation: NA, not available product (Table 4). Interestingly, we noted that all the CTCL patients were negative for both HTLV-I gag DNA and antibodies reactive with gag gene-encoded proteins p19 and p24, an observation confirming that these individuals were not exposed to HTLV-I gag proteins. Conversely, morethan halfof these patients have developed antibodies reactive with t d r e x proteins, suggesting that at some point in time that these t d r e x containing genes have been expressed as proteins in vivo. Both of the pX-encoded products (tax and rex proteins) have an important role in neoplastic T-cell activation. The p40tar protein functions as a transcriptional activator for its own promotor as well as several other genes such as IL-2, IL-2R, c-fos, The protein p27 rex is required for cytoplasmic expression of incompletely spliced viral mRNAs that encode structural proteins. Rex activity is mediated by cis-acting RNA signal sequence, which is bound specifically by rex protein.36Rex also stabilizes mRNA of the IL-2Ra chain.37It has been established that pX ( t d r e x ) gene of HTLV-I is capable and sufficient for immortalization of primary human CD4+ cord blood lymphocytes in culture in absence of HTLV-I structural genes.38We suggest that expression of the t d r e x region may be responsible for the maintenance of the malignant state in CTCL, as was suggested for patients with ATL.39Whether the origin of the tadrex genes is from a exogenous or endogenous source is not clear. If these sequences were introduced via prototypic HTLV-I infection, then the deletion must have occured before the diagnosis of MF was made, because we detected HTLV-I t d r e x gene in 30% (3/10) of skin biopsies from REFERENCES l . Edelson RL: Cutaneous T-cell lymphomas: Perspectives. Ann Intern Med 83:548, 1975 2. Kuzel TM, Roenigk HH Jr. Rosen ST: Mycosis fungoides and the SCzary syndrome: A review of pathogenesis, diagnosis and therapy. J Clin Oncol 9: 1298, 1991 3 . Abrams JT, Lessin S, Ghosh SK, Ju W, Vonderheid EC, Nowell P, Murphy G, Elfenbein B, DeFreitas E: A clonal CM-positive T-cell line established from the blood of a patient with Sdzary syndrome. J Invest Dermatol 96:31, 1991 4. Manzari V, Gismondi A, Barillari G, Morrone S, Modesti A, Albonici L, DeMarchis L, Fazio V, Gradilone A, Zani M, Frati L, Santoni A: HTLV-V: A new human retrovirus isolated in a tacnegative T-cell lymphomdleukemia. Science 238: 158I , 1987 5. Hall W, Liu CR, Schneewind 0, Takahashi H, Kaplan MH. Roupe G, Vahlne A: Deleted HTLV-I provirus in blood and cutaneous lesions of patient with mycosis fungoides. Science 253:317, 1991 6. Zucker-Franklin D, Coutavas EE, Rush MG, Zou Zias DC: Detection of human T-lymphotropic virus-like particles in cultures of peripheral blood lymphocytes from patients with mycosis fungoides. Proc Natl Acad Sci USA 88:7630, 1991 7. Zucker-Franklin D, Hooper WC, Evatt BL: Human lymphotropic retroviruses associated with mycosis fungoides: Evidence that human T-cell lymphotropic virus type I1(HTLV-11) as well as HTLV-I may play a role in the disease. Blood 80: 1537, 1992 8. Pancake BA, Zucker-Franklin D: HTLV tax and mycosis fungoides. N Engl J Med 329:580, 1993 9. Lange-Wantzin G , Thomsen K, Nissen NI, Saxinger D, Gallo RC: Occurrance of human T-cell lymphotropic virus (type I) antibodies in cutaneous T cell lymphoma. J AmAcad Dermatol 15598, 1986 10. Saxinger WC, Lange-Wantzin GL, Thomsen K, Hoh M, Gallo RC: Occurrance of HTLV-I antibodies in Danish patient with cutaneous T-cell lymphoma. Scand J Haematol 34:455, 1985 1 1. Abrams JT, Lessin SR. Ghosh SK, Nowell PC, Ju W, Vonderheid EC, Rook AH, DeFreitas E: Malignant and non malignant T cell lines from human T cell lymphotropic virus type I-negative patient with SBzary syndrome. J Immunol 146:1455, 1991 12. Abbott MA, Poiesz BJ, Byrne BC, Kwok S, Sninsky JJ, Ehrlich GD: Enzymatic gene amplification: Qualitative and quantitative methods for detective proviral DNA amplified in vitro. J Infect Dis 158:1158, 1988 13. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N: Enzymatic amplification of beta-globin genomic sequences on restriction site analysis for diagnosis of sickle cell anemia. Science 230: 1350, 1985 14. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chlroformextraction. Anal Biochem 162:156, 1987 15. Wang AM, Dogle MV, Mark DF: Quantitation of mRNA by From www.bloodjournal.org by guest on June 14, 2017. For personal use only. HTLV-1 T A X ~ R E XIN CTCL the polymerase chain reaction. Proc Natl Acad Sci USA 86:9717, 1989 16. Sanger F, Nicklen S, Coulsen AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 745463, 1977 17. Verma IM: Studies on reverse transcriptase of RNA tumor viruses. 111. Properties of purified Moloney murine leukemia virus DNA polymerase and associated RNase H. J Virol 152343, 1975 18. Okayama A, Chen YA, Tachibana N, Shioiri S, Lee T, Tsuda K, Essex M: High incidence of antibodies to HTLV-I tax in blood relatives of adult T cell leukemia patients. J Infect Dis 163:47, 1991 19. Kinoshita T, Shimoyama M, Tobinai K, Ito M, Ito S-I, Ikeda S, Tajima K, Shimotohno K, Sugimura T: Detection of mRNA for the tax'hex' gene of human T-cell leukemia virustype I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carrier by using the polymerase chain reaction. Proc Natl Acad Sci USA 865620, 1989 20. Franchini G, Wong-Staal F, Gallo RC: Human T-cell leukemia virus (HTLV-1) transcripts in fresh and cultured cells of patients with adult T-cell leukemia. Proc Natl Acad Sci USA 81:6207, 1984 21. Yoshida M, Miyoshi I, Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication inthe disease. Proc Natl Acad Sci USA 79:2031, 1982 22. Poiesz BJ, Ruscetti W ,Gazdar AF,Bunn PA, Minna JD, Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77:7415, 1980 23. Yoshida M, Seiki M, Yamaguchi Y, Takatsuki K: Monoclonal integration of HTLV in all primary tumors of adult T-cell leukemia suggests causative role of HTLV in the disease: Proc Natl Acad Sci USA 81:2534, 1984 24. Capesius C, Saal F, Macro E, Bazarbachi A, Lasneret J, Laroche L, Gessain A, Hozman F, Penes J: No evidence for HTLV-I infection in 24 cases of French and Portuguese mycosis fungoides and SCzary syndrome (as seen in France). Leukemia 5:416, 1991 25. Lisby G, Reitz MS Jr. Vejlsgaard GL: No detection of HTLVI DNA in punch skin biopsies from patient with cutaneous T-cell lymphoma by the polymerase chain reaction. J Invest Dermatol 98:417, 1992 26. Seiki M, Hattori S, Hirayama Y , Yoshida M:Human adult T-cell leukemia virus: Complete nucleotide sequence of the previous genome integrated in leukemia cell DNA, Proc Natl Acad Sci USA 80:3618, 1983 27. Seiki M, Hikikoshi A, Taniguchi T, Yoshida M: Expression 267 1 ofthe pX gene of HTLV-I: General splicing mechanism in the HTLV family. Science 228:1532, 1985 28. Chen ISY, Cann A J , Shah NP, Gaynor RB: Functional relationship of HTLV-I X and adenovirus EIA proteins in transcriptional activation. Science 230:570, 1985 29. Inoue J, Yoshida M, Seiki M: Transcriptional (P40x) and post-transcriptional (P 27x-111) regulation are required for the expression and replication of human T-cell leukemia virus type I genes. h o c Natl Acad Sci USA 84:3653, 1987 30. Bemhard H: Selective extraction of polyoma DNA from infected mouse cell culture. J Mol Biol 26:365, 1967 31. Baltimore D: Retroviruses and retrotransposons: The role of reverse transcriptase in shaping the eukaryotic genome. Cell 40:481, 1985 32. Chandra P, Steel L: Purification, biochemical characterization and serological analysis of cellular deoxyribonucleic acid polymerases and a reverse transcriptase from spleen of a patient with myelofibrotic syndrome. Biochem J 167513, 1977 33. Maruyama M, Shibuya H, Harada H, Hatakeyama M, Seiki M, Fujita T, Inoue J, Yoshida M, Tanaguchi T: Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-I encoded p40x and T3Ri complex triggering. Cell 48:343, 1987 34. Cross SL, Feinberg MB, Wolf JB, Holbrook NI, Wong-Staal F, Leonard WJ: Regulation of the humaninterleukin-2 receptor alpha chain promoter: Activation of a nonfunctional promoter by the transactivator gene of HTLV-I. Cell 49:41, 1987 35. Nagata K, Ohtani K, Nakamura M, Sagamura K: Activation of endogeneous c-fos protooncogene expression by human T cell leukemia virus type-I encoded p40tax protein in the human T cell line, Jurkat. J Virol 63:3220, 1989 36. Grassman R, Berchtold S, Aepinus C, Ballaun C, Boehnlein E, Fleckenstein B: In vitro binding of human T-cell leukemia virus type rex proteins to the rex-response element of viral transcripts. J Virol 65:3721, 1991 37. Kanamori H, Suzuki N, Siomi H, Nosaka T, Sato A, Sabe H, Hatanaka M, Honjo T HTLV-I p27rex stabilizes human interleukin2 receptor alpha-chain mRNA. EMBO J 9:4161, 1990 38. Grassman R, Berchtold S, Radant I, Alt M, Fleckenstein B, Sodroski JG, Haseltine WA, Ramstedt V: Role of human T-cell leukemia virus type I X region proteins in immortalization of primary human lymphocytes in culture. J Virol 66:4570, 1992 39. Korber B, Okayama A, Donnelly R, Tachibana N, Essex M: Polymerase chain reaction analysis of defective human T-cell leukemia virus type I proviral genomes in leukemic cells of patients with adult T-cell leukemia. J Virol 655471, 1991 From www.bloodjournal.org by guest on June 14, 2017. For personal use only. 1994 84: 2663-2671 Human T-cell leukemia virus type I tax/rex DNA and RNA in cutaneous T- cell lymphoma SK Ghosh, JT Abrams, H Terunuma, EC Vonderheid and E DeFreitas Updated information and services can be found at: http://www.bloodjournal.org/content/84/8/2663.full.html Articles on similar topics can be found in the following Blood collections Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.